European Atherosclerosis Society
@eassociety.bsky.social
Many patients use supplements, and recent studies have addressed their impact on LDL-C. Current evidence shows no relevant effect of diet composition on LDL cholesterol. The class III recommendation is an important novel part of the 2025 Updated Guidelines. Read more here: eas.to/guidelines-2...
October 2, 2025 at 9:13 AM
Many patients use supplements, and recent studies have addressed their impact on LDL-C. Current evidence shows no relevant effect of diet composition on LDL cholesterol. The class III recommendation is an important novel part of the 2025 Updated Guidelines. Read more here: eas.to/guidelines-2...
The EAS Advanced Courses on Rare Lipid Disorders continue their mission. On November 28, we welcome you to Berlin for the next course, hosted in collaboration with our German colleagues. Find full details and register here: www.dach-praevention.eu/eas-course/
October 2, 2025 at 7:25 AM
The EAS Advanced Courses on Rare Lipid Disorders continue their mission. On November 28, we welcome you to Berlin for the next course, hosted in collaboration with our German colleagues. Find full details and register here: www.dach-praevention.eu/eas-course/
Discover the EAS LatAm Chapter and connect with their representatives. Gain first-hand insights from them on the Focused Update of the ESC/EAS Guidelines for the management of dyslipidaemias: eas.to/guidelines-2...
October 1, 2025 at 12:46 PM
Discover the EAS LatAm Chapter and connect with their representatives. Gain first-hand insights from them on the Focused Update of the ESC/EAS Guidelines for the management of dyslipidaemias: eas.to/guidelines-2...
Kitty Almer tells us about the importance of high-level events such as last week’s in Brussels, emphasizing that evidence must be taken into account in policymaking.
September 30, 2025 at 12:33 PM
Kitty Almer tells us about the importance of high-level events such as last week’s in Brussels, emphasizing that evidence must be taken into account in policymaking.
Great mentors and researchers shape the future of science. Two weeks remain to nominate for the Anitschkow Prize 2026. Think of the mentor or researcher who inspired you - now is your chance to give them the recognition they deserve: eas.to/Anitschkow20...
September 30, 2025 at 8:17 AM
Great mentors and researchers shape the future of science. Two weeks remain to nominate for the Anitschkow Prize 2026. Think of the mentor or researcher who inspired you - now is your chance to give them the recognition they deserve: eas.to/Anitschkow20...
Don’t miss your chance to join the Advanced Course on non-classical risk factors in Vienna, October 27! This is not your typical course. Limited places available – once we’re full, that’s it. The next opportunity like this may be a long way off. Secure your spot now: eas.to/NCRFATReg
September 29, 2025 at 10:47 AM
Don’t miss your chance to join the Advanced Course on non-classical risk factors in Vienna, October 27! This is not your typical course. Limited places available – once we’re full, that’s it. The next opportunity like this may be a long way off. Secure your spot now: eas.to/NCRFATReg
Join us today at 17:00 CET for an insightful webinar exploring the latest Lipoprotein(a)-related guideline recommendations. You can still register here: eas.to/WebSep29Reg
September 29, 2025 at 8:01 AM
Join us today at 17:00 CET for an insightful webinar exploring the latest Lipoprotein(a)-related guideline recommendations. You can still register here: eas.to/WebSep29Reg
Prof. Mafalda Bourbon shares the outcomes of the high-level event at the European Parliament. She notes the solidarity across our community - patients, clinicians, and scientists - along with the goodwill of the MEP Group, and underlines prevention priorities, including FH screening for children.
September 26, 2025 at 9:57 AM
Prof. Mafalda Bourbon shares the outcomes of the high-level event at the European Parliament. She notes the solidarity across our community - patients, clinicians, and scientists - along with the goodwill of the MEP Group, and underlines prevention priorities, including FH screening for children.
Prof. Børge Nordestgaard emphasized that patients must be at the centre of the upcoming EU CV Health Plan, and our society supports them with evidence. Yesterday, their voices were heard through short, emotional testimonies that humanised the stakes of missed or late diagnoses. We are proud of you!
September 26, 2025 at 9:24 AM
Prof. Børge Nordestgaard emphasized that patients must be at the centre of the upcoming EU CV Health Plan, and our society supports them with evidence. Yesterday, their voices were heard through short, emotional testimonies that humanised the stakes of missed or late diagnoses. We are proud of you!
The EU High-Level Event on cardiovascular health is happening right now at the European Parliament 🇪🇺. Patients, policymakers & experts are coming together to highlight why early screening for FH and Lp(a) must become a European priority.
September 25, 2025 at 3:06 PM
The EU High-Level Event on cardiovascular health is happening right now at the European Parliament 🇪🇺. Patients, policymakers & experts are coming together to highlight why early screening for FH and Lp(a) must become a European priority.
From evidence to policy – and from policy to practice! Our work goes beyond generating scientific evidence. We share the knowledge with policymakers to help shape stronger cardiovascular health strategies at the European level. You are warmly invited to join the meeting online: eas.to/EP25SepReg
September 25, 2025 at 12:14 PM
From evidence to policy – and from policy to practice! Our work goes beyond generating scientific evidence. We share the knowledge with policymakers to help shape stronger cardiovascular health strategies at the European level. You are warmly invited to join the meeting online: eas.to/EP25SepReg
Certain cancers increase CVD risk, partly beyond traditional risk factors. Earlier guidelines gave no advice on lipid lowering in survivors, but new evidence now allows updated recommendations. Read more here: eas.to/guidelines-2...
September 25, 2025 at 8:40 AM
Certain cancers increase CVD risk, partly beyond traditional risk factors. Earlier guidelines gave no advice on lipid lowering in survivors, but new evidence now allows updated recommendations. Read more here: eas.to/guidelines-2...
It’s FH Awareness Day! ♥️ We’re celebrating with you during our webinar this afternoon. Who’s joining us? If you haven’t registered yet, this is your last chance: eas.to/WebSep24Reg
September 24, 2025 at 7:54 AM
It’s FH Awareness Day! ♥️ We’re celebrating with you during our webinar this afternoon. Who’s joining us? If you haven’t registered yet, this is your last chance: eas.to/WebSep24Reg
We're launching the first online version of the Rare Lipid Disorder Course as part of FH Awareness Week 2025! This self-paced, multilingual course is designed to improve global access to expert knowledge on rare lipid disorders, building on successful live courses. eas-society.org/course/onlin...
September 23, 2025 at 11:08 AM
We're launching the first online version of the Rare Lipid Disorder Course as part of FH Awareness Week 2025! This self-paced, multilingual course is designed to improve global access to expert knowledge on rare lipid disorders, building on successful live courses. eas-society.org/course/onlin...
Listen to this special FH Awareness Week episode of AtheroTalk featuring Prof. Steve Humphries. He shares valuable insights into familial hypercholesterolaemia (FH) and introduces the newly established EAS Paediatric Lipid Working Group.
🎧 eas.to/ATHTalkE18S
🎧 eas.to/ATHTalkE18A
🎧 eas.to/ATHTalkE18Y
🎧 eas.to/ATHTalkE18S
🎧 eas.to/ATHTalkE18A
🎧 eas.to/ATHTalkE18Y
September 23, 2025 at 7:51 AM
Listen to this special FH Awareness Week episode of AtheroTalk featuring Prof. Steve Humphries. He shares valuable insights into familial hypercholesterolaemia (FH) and introduces the newly established EAS Paediatric Lipid Working Group.
🎧 eas.to/ATHTalkE18S
🎧 eas.to/ATHTalkE18A
🎧 eas.to/ATHTalkE18Y
🎧 eas.to/ATHTalkE18S
🎧 eas.to/ATHTalkE18A
🎧 eas.to/ATHTalkE18Y
🚨 Join us for EAS FH Week 2025! FH is still underdiagnosed and undertreated - it’s time for action. Together, we’re raising awareness, shaping policy, and driving better care: eas.to/FHWeek2025
September 22, 2025 at 8:49 AM
🚨 Join us for EAS FH Week 2025! FH is still underdiagnosed and undertreated - it’s time for action. Together, we’re raising awareness, shaping policy, and driving better care: eas.to/FHWeek2025
EAS President Prof. Børge Nordestgaard will speak at the European Parliament on 25 September 2025, alongside Profs. Albert Wiegman and Florian Kronenberg, at a high-level meeting on advancing cardiovascular prevention, hosted by MEPs Romana Jerković and Tomislav Sokol.
September 19, 2025 at 3:02 PM
EAS President Prof. Børge Nordestgaard will speak at the European Parliament on 25 September 2025, alongside Profs. Albert Wiegman and Florian Kronenberg, at a high-level meeting on advancing cardiovascular prevention, hosted by MEPs Romana Jerković and Tomislav Sokol.
People with HIV have double the ASCVD risk, leading to a 2019 Class IIa recommendation for statins in dyslipidaemia. After the REPRIEVE trial, 2025 guidelines now give a Class I recommendation for statins in all ≥40-year-olds with HIV. Read more: eas.to/guidelines-2...
September 19, 2025 at 9:28 AM
People with HIV have double the ASCVD risk, leading to a 2019 Class IIa recommendation for statins in dyslipidaemia. After the REPRIEVE trial, 2025 guidelines now give a Class I recommendation for statins in all ≥40-year-olds with HIV. Read more: eas.to/guidelines-2...
Do you know an outstanding scientist whose work has significantly advanced the field of atherosclerosis and cardiovascular research? We are now accepting nominations for the 2026 Anitschkow Prize! This is your chance to highlight and honor a colleague, mentor, or peer: eas.to/Anitschkow20...
September 16, 2025 at 10:04 AM
Do you know an outstanding scientist whose work has significantly advanced the field of atherosclerosis and cardiovascular research? We are now accepting nominations for the 2026 Anitschkow Prize! This is your chance to highlight and honor a colleague, mentor, or peer: eas.to/Anitschkow20...
We’re thrilled to welcome Marwa Sadik, HoFH Patient Ambassador, as a special guest at our upcoming FH Week webinar. Marwa will share her powerful personal journey with homozygous familial hypercholesterolemia, offering valuable insights into living with this rare condition. eas.to/WebSep24Reg
September 15, 2025 at 11:45 AM
We’re thrilled to welcome Marwa Sadik, HoFH Patient Ambassador, as a special guest at our upcoming FH Week webinar. Marwa will share her powerful personal journey with homozygous familial hypercholesterolemia, offering valuable insights into living with this rare condition. eas.to/WebSep24Reg
In this episode of AtheroTalk, we explore a new Consensus Statement that proposes a three-stage, holistic framework for understanding and managing metabolic disease.
🎧 eas.to/ATHTalkE17S
🎧 eas.to/ATHTalkE17A
🎧 eas.to/ATHTalkE17Y
🎧 eas.to/ATHTalkE17S
🎧 eas.to/ATHTalkE17A
🎧 eas.to/ATHTalkE17Y
September 15, 2025 at 7:32 AM
In this episode of AtheroTalk, we explore a new Consensus Statement that proposes a three-stage, holistic framework for understanding and managing metabolic disease.
🎧 eas.to/ATHTalkE17S
🎧 eas.to/ATHTalkE17A
🎧 eas.to/ATHTalkE17Y
🎧 eas.to/ATHTalkE17S
🎧 eas.to/ATHTalkE17A
🎧 eas.to/ATHTalkE17Y
High-dose icosapent ethyl is now recommended for high-risk patients with elevated triglycerides, based on REDUCE-IT, while volanesorsen is advised for FCS patients to reduce triglycerides and pancreatitis risk, per the APPROACH trial. Read more here: eas.to/guidelines-2...
September 13, 2025 at 8:43 AM
High-dose icosapent ethyl is now recommended for high-risk patients with elevated triglycerides, based on REDUCE-IT, while volanesorsen is advised for FCS patients to reduce triglycerides and pancreatitis risk, per the APPROACH trial. Read more here: eas.to/guidelines-2...
It’s unclear if lowering Lp(a) reduces ASCVD or AVS risk, so managing other risk factors and lowering LDL-C remains key. Despite earlier concerns, statins don’t raise Lp(a), and high-risk patients should still use high-intensity statins: eas.to/guidelines-2...
September 11, 2025 at 10:27 AM
It’s unclear if lowering Lp(a) reduces ASCVD or AVS risk, so managing other risk factors and lowering LDL-C remains key. Despite earlier concerns, statins don’t raise Lp(a), and high-risk patients should still use high-intensity statins: eas.to/guidelines-2...
Prof. Šekib Sokolović emphasizes the
importance of proper dissemination of the Focused
Update of the 2019 ESC/EAS Guidelines at local levels.
Learn more about the key messages yourself:
eas.to/guidelines-2...
importance of proper dissemination of the Focused
Update of the 2019 ESC/EAS Guidelines at local levels.
Learn more about the key messages yourself:
eas.to/guidelines-2...
September 10, 2025 at 4:21 PM
Prof. Šekib Sokolović emphasizes the
importance of proper dissemination of the Focused
Update of the 2019 ESC/EAS Guidelines at local levels.
Learn more about the key messages yourself:
eas.to/guidelines-2...
importance of proper dissemination of the Focused
Update of the 2019 ESC/EAS Guidelines at local levels.
Learn more about the key messages yourself:
eas.to/guidelines-2...
Join us for a special session in recognition of Familial Hypercholesterolaemia (FH) Awareness Week. This webinar features the recorded session from EAS 2025 in Glasgow, highlighting key insights into FH diagnosis, treatment, and global strategies.
Register here: eas.to/WebSep24Reg
Register here: eas.to/WebSep24Reg
September 9, 2025 at 6:36 PM
Join us for a special session in recognition of Familial Hypercholesterolaemia (FH) Awareness Week. This webinar features the recorded session from EAS 2025 in Glasgow, highlighting key insights into FH diagnosis, treatment, and global strategies.
Register here: eas.to/WebSep24Reg
Register here: eas.to/WebSep24Reg